Clinical Trial Update: Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gefitinib in combination with PEG-Interferon Alfa-2b for unresectable or metastatic kidney cancer was terminated; results were posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer

Drugs mentioned

• Gefitinib (Gefitinib)
• PEG-Interferon alfa-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: California Cancer Consortium | Conditions: Kidney Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-03-17